A vaccine given during pregnancy is substantially lowering hospital admissions among newborns with respiratory syncytial virus (RSV), with UK health officials confirming a decrease of more than 80 per cent. The jab, provided to pregnant women from 28 weeks of gestation since 2024, protects babies from birth by boosting maternal immunity and transferring immunity through the placenta. A significant recent study examining nearly 300,000 births across England between September 2024 and March 2025 has shown the vaccine’s “excellent protection” during the timeframe when infants are particularly susceptible to the virus. RSV affects roughly 50 per cent of newborns and remains one of the leading causes of hospital admission in babies under one year old, with more than 20,000 serious cases recorded annually across the UK.
How the immunisation safeguards at-risk babies
RSV, or respiratory syncytial virus, is a frequent respiratory infection that affects approximately half of all newborns in their first few months of life. The virus can range from causing mild cold-like symptoms to triggering severe chest infections that leave babies struggling to breathe and feed. In the most serious cases, the inflammation in the lungs becomes life-threatening, with small numbers of babies dying from the infection each year. Dr Conall Watson, national programme lead for RSV at the UK Health Security Agency, emphasises the deeply distressing nature of severe RSV infections: “In babies with severe infections you can see their chest and lungs struggling, as they try to pull enough oxygen in. This is extremely frightening as a parent, frightening with good reason.”
The pregnancy vaccine works by activating the mother’s body’s defences to produce protective antibodies, which are then transferred to the developing baby through the placenta. This maternal immunity provides newborns with immediate protection from the point of delivery, precisely when they are highly susceptible to RSV. The latest research demonstrates that protection reaches nearly 85 per cent when the vaccine is administered four weeks or more before delivery. Even shorter intervals between vaccination and birth can still provide substantial defence, with evidence indicating that a fortnight’s interval is sufficient to shield babies born slightly early. Dr Watson recommends pregnant women to receive the vaccine on schedule, whilst noting that protection remains possible even if given later in the third trimester.
- Nearly 85 per cent protection when vaccinated four weeks before birth
- Antibodies from the mother transferred through the placenta protect newborns from birth
- Protection achievable with 2-week gap before early delivery
- Vaccination during the third trimester still provides significant infant protection
Compelling evidence from current research
The efficacy of the RSV vaccine administered during pregnancy has been demonstrated through a thorough investigation undertaken in England, examining data from close to 300,000 babies born between September 2024 and March 2025. This represents approximately nine out of ten of all births during that half-year window, providing robust and representative evidence of the vaccine’s practical effectiveness. The study’s results have been supported by the UK Health Security Agency as showing “excellent protection” for newborns during their most vulnerable early months. The scope of this study offers healthcare professionals and expectant parents with assurance in the vaccine’s demonstrated effectiveness across different groups and contexts.
The results reveal a compelling picture of the vaccine’s protective effectiveness. More than 4,500 babies were admitted to hospital with RSV throughout the study period, with the vast majority being infants whose mothers had not received the vaccination. This marked difference emphasises the vaccine’s essential role in protecting against serious illness in newborns. The reduction in hospital admissions above 80 per cent represents a significant public health achievement, possibly preventing thousands of infants from experiencing the distressing and potentially serious symptoms linked to severe RSV infection. These findings strengthen the importance of the vaccination programme launched in the UK in 2024.
Research approach and coverage
The research examined birth and hospital admission records from England over a six-month period, capturing data on approximately 90 per cent of all births during this timeframe. By examining around 300,000 babies born to vaccinated and unvaccinated mothers, researchers were in a position to determine direct comparisons of RSV infection levels and hospital admissions. The large sample size and comprehensive nature of the data collection ensured that findings were statistically robust and representative of the broader population, rather than isolated cases or small subgroups.
The study specifically tracked hospital admissions for RSV among infants born to mothers who had received the vaccine at varying intervals before delivery. This allowed researchers to identify the minimum time required between vaccination and birth for optimal protection, as well as to determine whether protection continued to be effective with reduced timeperiods. The methodology measured practical outcomes rather than experimental conditions, providing practical evidence of how the vaccine functions when administered across diverse clinical settings and patient circumstances throughout the third trimester of pregnancy.
| Key Finding | Impact |
|---|---|
| Nearly 85% protection with four-week vaccination interval | Optimal protection achieved when vaccine given one month before delivery |
| Over 80% reduction in newborn hospital admissions | Thousands of infants prevented from serious RSV-related illness annually |
| Vast majority of hospitalisations in unvaccinated mothers’ babies | Clear evidence of vaccine efficacy in preventing severe infection |
| Protection possible with two-week pre-birth interval | Meaningful safeguard even for early deliveries and shorter vaccination windows |
Grasping RSV and the dangers
Respiratory syncytial virus, commonly referred to as RSV, is among the primary causes of hospitalisation in infants under one year of age across the United Kingdom. The virus affects approximately half of all newborns during their early months of life, with severity changing substantially from mild cold-like symptoms to serious, potentially fatal chest infections. Over 20,000 infants require serious hospital treatment for RSV annually in the UK alone, placing considerable pressure on paediatric wards and neonatal units during peak seasons.
The infection produces deep inflammation in the lungs and airways, making it dangerously difficult for infected babies to breathe and feed adequately. Parents commonly see their babies fighting for breath, their chests rising whilst they work to get adequate oxygen into their compromised lungs. Whilst most infants recover with palliative treatment, a limited though important group succumb from RSV complications annually, making immunisation programmes a essential public health objective for safeguarding the most vulnerable and youngest people in our communities.
- RSV triggers inflammation in lungs, causing severe breathing difficulties in babies
- Half of all newborns acquire the virus during their first few months alive
- Symptoms range from mild colds to life-threatening chest infections requiring hospitalisation
- More than 20,000 UK babies need serious hospital treatment for RSV annually
- Small numbers of infants die from RSV related complications annually in the UK
Uptake rates and specialist advice
Since the RSV vaccine programme commenced in 2024, health officials have emphasised the significance of pregnant women getting their jab at the ideal time for maximum protection. Dr Conall Watson, lead for the national programme for RSV at the UK Health Security Agency, has underscored that timing is crucial for guaranteeing newborns receive the maximum immunity from birth. Whilst the research shows that vaccination performed at least four weeks prior to delivery provides approximately 85% protection, experts advise women to get their vaccine as soon as feasible from 28 weeks of pregnancy forward to increase the antibodies passed to their babies via the placenta.
The guidance from public health bodies remains clear: pregnant women ought to prioritise vaccination during their third trimester, even if circumstances mean they cannot receive the jab at the optimal time. Dr Watson has reassured pregnant women that protection is still achievable with shorter intervals between immunisation and delivery, including even a fourteen-day window for those delivering slightly early. This flexible approach acknowledges the practical demands of pregnancy whilst maintaining strong protection for vulnerable newborns during their most critical early months when RSV represents the highest danger of serious illness.
Regional variations in vaccine uptake
Whilst the RSV vaccine programme has been implemented across England, uptake rates and deployment schedules have varied across various areas and NHS trusts. Certain regions have achieved higher vaccination coverage among eligible pregnant women, whilst others remain focused to increase awareness and availability of the jab. These geographical variations reflect differences across medical facilities, engagement approaches, and local engagement efforts, though the national data demonstrates robust and reliable protection regardless of geographical location.
- NHS trusts deploying diverse outreach initiatives to connect with pregnant women
- Geographic variations in immunisation take-up throughout England necessitate strategic intervention
- Regional health providers modifying schemes to suit community needs and circumstances
Real-world impact and parent viewpoints
The vaccine’s remarkable effectiveness translates into real advantages for families across the United Kingdom. With more than 20,000 babies admitted to hospital annually due to RSV prior to the launch of this protective measure, the 80% decrease in admissions represents thousands of infants spared from severe infection. Parents no longer face the distressing scenario of watching their newborns struggle for breath or struggle to eat, symptoms that mark severe RSV infections. The vaccine has fundamentally shifted the landscape of neonatal breathing health, providing expectant mothers a active means to shield their youngest infants during those crucial first weeks.
For families like that of Malachi, whose acute RSV infection caused profound brain damage, the vaccine’s introduction carries profound emotional significance. His mother’s promotion of the jab highlights the transformative consequences that preventable illness can have on young children and their families. Whilst Malachi’s experience predates the vaccine programme, his story strikes a chord with parents now given protection. The knowledge that such significant complications—hospital stay, oxygen dependency, neurological damage—are now mostly preventable has provided considerable reassurance to women in pregnancy in their late pregnancy, transforming what was once an unavoidable seasonal threat into a controllable health concern.